Company Bellerophon Therapeutics LLC Nasdaq
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- | - |
|
05-02 | North American Morning Briefing : Stock Futures -2- | DJ |
04-25 | North American Morning Briefing : More Tech -2- | DJ |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Craig Jalbert
CEO | Chief Executive Officer | 63 | - |
Martin Dekker
CTO | Chief Tech/Sci/R&D Officer | 51 | 28/01/15 |
Edwin L. Parsley
CTO | Chief Tech/Sci/R&D Officer | 63 | - |
Bobae Kim
LAW | General Counsel | 42 | 31/08/22 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Naseem Amin
CHM | Chairman | 62 | 28/06/15 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 12,232,648 | 10,394,477 ( 84.97 %) | 0 | 84.97 % |
Company contact information
Bellerophon Therapeutics, Inc.
184 Liberty Corner Road Suite 302
07059, Warren
+908 574 4770
http://www.bellerophon.com![address Bellerophon Therapeutics LLC](https://cdn.zonebourse.com/static/address/20708472.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+16.06% | 122B | |
+18.99% | 113B | |
+18.95% | 26.49B | |
-23.41% | 19.4B | |
-19.03% | 16.24B | |
-19.91% | 15.4B | |
-46.14% | 15.15B | |
+64.34% | 14.93B | |
+5.31% | 13.52B |
- Stock Market
- Equities
- BLPH Stock
- Stock
- Company Bellerophon Therapeutics LLC